Synopsis of recent research by authors named "Helen Blair"
- Helen Blair's research primarily focuses on the molecular and metabolic vulnerabilities in various types of leukemia and brain tumors, including group 3 medulloblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), seeking to identify novel therapeutic targets and strategies.
- Recent findings suggest that targeting specific genetic and metabolic pathways, such as MYC-dependent metabolism, the AP-1-RUNX1 axis in FLT3-ITD positive AML, and combined therapies involving p53 reactivation, could improve treatment outcomes in high-risk leukemia cases.
- Additionally, Blair's work highlights the importance of gene regulatory networks in predicting treatment responses and the potential of innovative drug testing models, such as human mesenchymal spheroids, to reduce reliance on animal models in leukemia research.
